Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - tabletten - ruxolitinibum 5 mg ut ruxolitinibi phosphas, lactosum monohydricum 71.45 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.32 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - tabletten - ruxolitinibum 15 mg ut ruxolitinibi phosphas, lactosum monohydricum 214.35 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.97 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - tabletten - ruxolitinibum 20 mg ut ruxolitinibi phosphas, lactosum monohydricum 285.8 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 1.29 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - tabletten - ruxolitinibum 10 mg ut ruxolitinibi phosphas, lactosum monohydricum 142.9 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.65 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - andere dermatologische präparate - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Europäische Union - Deutsch - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (als phosphat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastische mittel - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi ist angezeigt für die behandlung von erwachsenen patienten mit polycythaemia vera, die resistent oder intolerant gegenüber hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Europäische Union - Deutsch - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastische mittel - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - fedratinibum - hartkapseln - fedratinibum 100 mg ut fedratinibi dihydrochloridum monohydricum, cellulosum microcristallinum silicificatum, natrii stearylis fumaras corresp. natrium 0.18 mg, kapselhülle: gelatina, e 172 (rubrum), e 171, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - primäre oder sekundäre myelofibrose - synthetika

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

esteve pharmaceuticals gmbh (8146447) - rifampicin-natrium - pulver zur herstellung einer infusionslösung - teil 1 - pulver zur herstellung einer infusionslösung; rifampicin-natrium (21830) 616,4 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

esteve pharmaceuticals gmbh (8146447) - rifampicin-natrium - pulver zur herstellung einer infusionslösung - teil 1 - pulver zur herstellung einer infusionslösung; rifampicin-natrium (21830) 308,2 milligramm